ArticleMarine drugs2026
Design and Synthesis of Marine Sarocladione Derivatives with Potential Anticancer Activity.
Xiao-Mei Liu, Wen-Xuan Li, Ling-Xiu Kong, Guan-Ying Han, Jinghan Gui, Xu-Wen Li
Abstract read
In one paragraphArticle in Marine drugs, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Xiao-Mei LiuState Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.
Wen-Xuan LiShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.
Ling-Xiu KongShandong Laboratory of Yantai Drug Discovery, Bohai Rim Advanced Research Institute for Drug Discovery, Yantai 264117, China.
Guan-Ying HanShandong Fengjin Biopharmaceuticals Co., Ltd., Yantai 264117, China.
Jinghan GuiState Key Laboratory of Chemical Biology, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, China.
Xu-Wen LiState Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China.ORCID 0000-0001-7919-9726 Funding
Fundamental Research Projects of Science & Technology Innovation and Development Plan in Yantai City 2023JCYJ057Key Marine Service Industry Program of Shandong Province 2025Key Research and Development Program of Shandong Province 2024CXPT028Key Research and Development Program of Shandong Province 2025CXPT012National Key Research and Development Program of China 2021YFF0502400National Natural Science Foundation of China 42576087Shandong Laboratory Program SYS202205Strategic Priority Research Program of the Chinese Academy of Sciences XDB1060000Taishan Scholars Program tsqn2023-12302Youth Fund of the Natural Science Foundation of Shandong Province ZR2023QD162
6 · The paper itselfAbstract
The discovery of structurally novel anti-tumor agents remains a crucial objective in cancer drug research. In this study, we systematically explored the bioactivity potential of sarocladione (
Indexed as
Antineoplastic AgentsAnimalsApoptosisAquatic OrganismsCell Line, TumorCell ProliferationDrug DesignDrug Screening Assays, AntitumorHCT116 CellsHumansStructure-Activity RelationshipAntineoplastic Agentsanticancer activityapoptosismarine natural productSARsarocladione
Identifiers
PMID41590745
PMCPMC12843125
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390